Transthoracic fine‐needle aspiration. Experience in a cancer center

John H Crosby, Bjarne Hager, Kari Høeg

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

The authors summarize 5 years' experience with transthoracic fine‐needle aspiration (TFNA) in 180 patients. Aspirated tumors tended to be large and peripheral. A large pneumothorax was seen after 4.3% of aspirations, and various minor complications followed another 23.3%. Emphysema was a significant risk factor for complications. Follow‐up confirmed 151 cancers, with a wide variety of origins and histologic types. In the diagnosis of cancer, TFNA cytology had a specificity of 100% and a sensitivity of 82%. Positive TFNA findings usually provided the earliest microscopic diagnosis of cancer or of cancer stage.

Original languageEnglish (US)
Pages (from-to)2504-2507
Number of pages4
JournalCancer
Volume56
Issue number10
DOIs
StatePublished - Jan 1 1985

Fingerprint

Neoplasms
Emphysema
Pneumothorax
Early Detection of Cancer
Cell Biology

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Transthoracic fine‐needle aspiration. Experience in a cancer center. / Crosby, John H; Hager, Bjarne; Høeg, Kari.

In: Cancer, Vol. 56, No. 10, 01.01.1985, p. 2504-2507.

Research output: Contribution to journalArticle

Crosby, John H ; Hager, Bjarne ; Høeg, Kari. / Transthoracic fine‐needle aspiration. Experience in a cancer center. In: Cancer. 1985 ; Vol. 56, No. 10. pp. 2504-2507.
@article{5623942f26354669ac5cf2dda2929382,
title = "Transthoracic fine‐needle aspiration. Experience in a cancer center",
abstract = "The authors summarize 5 years' experience with transthoracic fine‐needle aspiration (TFNA) in 180 patients. Aspirated tumors tended to be large and peripheral. A large pneumothorax was seen after 4.3{\%} of aspirations, and various minor complications followed another 23.3{\%}. Emphysema was a significant risk factor for complications. Follow‐up confirmed 151 cancers, with a wide variety of origins and histologic types. In the diagnosis of cancer, TFNA cytology had a specificity of 100{\%} and a sensitivity of 82{\%}. Positive TFNA findings usually provided the earliest microscopic diagnosis of cancer or of cancer stage.",
author = "Crosby, {John H} and Bjarne Hager and Kari H{\o}eg",
year = "1985",
month = "1",
day = "1",
doi = "10.1002/1097-0142(19851115)56:10<2504::AID-CNCR2820561030>3.0.CO;2-A",
language = "English (US)",
volume = "56",
pages = "2504--2507",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "10",

}

TY - JOUR

T1 - Transthoracic fine‐needle aspiration. Experience in a cancer center

AU - Crosby, John H

AU - Hager, Bjarne

AU - Høeg, Kari

PY - 1985/1/1

Y1 - 1985/1/1

N2 - The authors summarize 5 years' experience with transthoracic fine‐needle aspiration (TFNA) in 180 patients. Aspirated tumors tended to be large and peripheral. A large pneumothorax was seen after 4.3% of aspirations, and various minor complications followed another 23.3%. Emphysema was a significant risk factor for complications. Follow‐up confirmed 151 cancers, with a wide variety of origins and histologic types. In the diagnosis of cancer, TFNA cytology had a specificity of 100% and a sensitivity of 82%. Positive TFNA findings usually provided the earliest microscopic diagnosis of cancer or of cancer stage.

AB - The authors summarize 5 years' experience with transthoracic fine‐needle aspiration (TFNA) in 180 patients. Aspirated tumors tended to be large and peripheral. A large pneumothorax was seen after 4.3% of aspirations, and various minor complications followed another 23.3%. Emphysema was a significant risk factor for complications. Follow‐up confirmed 151 cancers, with a wide variety of origins and histologic types. In the diagnosis of cancer, TFNA cytology had a specificity of 100% and a sensitivity of 82%. Positive TFNA findings usually provided the earliest microscopic diagnosis of cancer or of cancer stage.

UR - http://www.scopus.com/inward/record.url?scp=0022367740&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022367740&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19851115)56:10<2504::AID-CNCR2820561030>3.0.CO;2-A

DO - 10.1002/1097-0142(19851115)56:10<2504::AID-CNCR2820561030>3.0.CO;2-A

M3 - Article

C2 - 4042073

AN - SCOPUS:0022367740

VL - 56

SP - 2504

EP - 2507

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 10

ER -